Atopic Dermatitis Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

1. Atopic Dermatitis Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight DelveInsight has launched a new report on ”Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2030”. DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast- 2030“ report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends. Geographies Covered: United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China. Some of the key Facts: 1.Market analysis study carried out by DI for the period of 2017-2030 shows that the Market size of Atopic Dermatitis was USD 2422 Million in 2017 in the 7MM 2.Market Size of Atopic Dermatitis was estimated to be 1038 USD Millions in 2017 in the United States.

2. 3.In the United States prevalent population of Atopic Dermatitis was found to be 19,460,609 in 2017. 4.As per DelveInsight estimates, higher prevalent population of uncontrolled Atopic Dermatitis is observed in United States as compared to EU5 countries and Japan. Request for free Sample Page: https://www.delveinsight.com/sample-request/atopic-dermatitis- ad-market Report Key Highlights:  In the coming years, Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market  The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis (AD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  Major players are involved in developing therapies for Atopic Dermatitis (AD). Launch of emerging therapies will significantly impact the Atopic Dermatitis (AD) market  A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atopic Dermatitis (AD)  Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities “According to DelveInsight’s findings, females are affected more as compared to males, in case of Atopic Dermatitis.” Request for free Sample Page: https://www.delveinsight.com/sample-request/atopic-dermatitis- ad-market Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood with changing severity over the years. In children under one year of age much of the body may be affected. As children get older, the back of the knees and front of the elbows are the most common areas affected. In adults the hands and feet are the most commonly affected areas. Scratching worsens symptoms and affected people have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma. The cause is unknown but believed to involve genetics, immune system dysfunction, environmental exposures, and difficulties with the permeability of the skin. If one identical twin is affected, there is

3. an 85% chance the other also has the condition. Those who live in cities and dry climates are more commonly affected. Exposure to certain chemicals or frequent hand washing makes symptoms worse. While emotional stress may make the symptoms worse. The disorder is not contagious. The diagnosis is typically based on the signs and symptoms. Request for free Sample Page: https://www.delveinsight.com/sample-request/atopic-dermatitis- ad-market Some of the Key Companies:  Pfizer  Novartis Pharmaceuticals  Daiichi Sankyo  AbbVie  PurGenesis Technologies  And Many others Drugs Covered:  Abrocitinib  ZPL389  DS-2741a  Upadacitinib  PUR0110  And Many Others Request for free Sample Page: https://www.delveinsight.com/sample-request/atopic-dermatitis- ad-market Table of Contents: 1.Key Insights 2.Executive Summary of Atopic Dermatitis (AD) 3.Competitive Intelligence Analysis for Atopic Dermatitis (AD) 4.Atopic Dermatitis (AD): Market Overview at a Glance 5.Atopic Dermatitis (AD): Disease Background and Overview 6.Patient Journey 7.Atopic Dermatitis (AD) Epidemiology and Patient Population 8.Treatment Algorithm, Current Treatment, and Medical Practices

4. 9.Unmet Needs 10.Key Endpoints of Atopic Dermatitis (AD) Treatment 11.Marketed Products 11.1. List of Marketed Products in the 7MM 11.2. Drug Name: Company Name 11.2.1. Product Description 11.2.2. Regulatory Milestones 11.2.3. Other Developmental Activities 11.2.4. Pivotal Clinical Trials 11.2.5. Summary of Pivotal Clinical Trial List to be continued in report 12.Emerging Therapies 12.1. Key Cross 12.2. Drug Name: Company Name 12.2.1. Product Description 12.2.2. Other Developmental Activities 12.2.3. Clinical Development 12.2.4. Safety and Efficacy 12.2.5. Product Profile List to be continued in report 13.Atopic Dermatitis (AD): Seven Major Market Analysis 14.Attribute analysis 15.7MM: Market Outlook 16.Access and Reimbursement Overview of Atopic Dermatitis (AD) 17.KOL Views 18.Market Drivers 19.Market Barriers 20.Appendix 21.DelveInsight Capabilities 22.Disclaimer 23.About DelveInsight

5. Request for Detailed TOC: https://www.delveinsight.com/sample-request/atopic-dermatitis-ad- market Related Reports:  Atopic Dermatitis (AD) – Epidemiology Forecast to 2030  Atopic Dermatitis (AD) – Pipeline Insights, 2020